Review of the current literature fails to show significant mortality benefit with any specific
vasopressor or inotropic in CS patients. The upcoming DOREMI 2 and levosimendan versus …

TEER remains a promising therapeutic option in cardiogenic shock complicated by
significant mitral regurgitation, but additional research is required to identify patient and …

Background Recent studies have shown improved outcomes in cardiogenic shock through
protocols directed toward early identification and initiation of mechanical circulatory support …

Background Patients with cardiogenic shock (CS) suffer high rates of in-hospital mortality,
with little evidence guiding management. The impact of valvular heart disease in patients …

The role of the beta-adrenergic signaling pathway in heart failure (HF) is pivotal. Early
blockade of this pathway with beta-blocker (BB) therapy is recommended as the first-line …

Cardiogenic shock is a primary cardiac disorder that results in both clinical and biochemical
evidence of tissue hypoperfusion and can lead to multi‐organ failure and death depending …

OBJECTIVES: Inotropic support is commonly used in patients with cardiogenic shock (CS).
High-quality data guiding the use of dobutamine or milrinone among this patient population …

Background Cardiogenic shock (CS) is associated with significant morbidity and mortality;
however, there are limited randomized data evaluating the association between sex and …

Cardiovascular diseases remain the leading cause of death globally, with acute myocardial
infarction being one of the most frequent. One of the complications that can occur after a …

This study aims to evaluate the difference between dobutamine and milrinone in patients
presenting with acute decompensated heart failure (AHF). Inotropes are indicated for …